FTB Monster: Ech #39;s Lab #12 - "Advanced Genetics: Squidman Rises"
We continue down the route of mad scientist and splice our DNA with that of various animals and monsters. What are the effects? Thank you for watching this s...

By: EchPlays

Excerpt from:
FTB Monster: Ech's Lab #12 - "Advanced Genetics: Squidman Rises" - Video

Recommendation and review posted by Bethany Smith

LONDON und LAUSANNE, Schweiz, July 8, 2014 /PRNewswire/ --

Investition soll Nutzung klinischer Analysen fr genetisch bedingte Krankheiten in Europa beschleunigen

Sophia Genetics, das fhrende europische Unternehmen im Bereich datengesttzter Medizin, hat in einer Serie-B-Finanzierungsrunde 13,75 Millionen US-Dollar an Mitteln beschafft, angefhrt durch Invoke Capital von Mike Lynch, Swisscom und Endeavour Vision.

Sophia Genetics ist ein Pionier in der datengesttzten Medizin, einem bergreifenden Gebiet, das umfangreiche Kompetenz mit Next Generation Sequencing (NGS) erfordert, kombiniert mit uerst genauen und skalierbaren voraussagenden Algorithmen zur Diagnose genetisch bedingter Erkrankungen. Mit dieser Investition verschafft sich Sophia Zugang zu Genalys, einem Unternehmen aus dem Portfeuille von Invoke, dessen in Cambridge angesiedelte Mathematiker Big-Data-Verfahren auf Genomdaten anwenden. Die Kombination bedeutet, dass Kliniker und Krankenhuser in ganz Europa Zugriff auf einen uerst genauen klinischen Analysedienst zur frhzeitigen Diagnose und optimierten Behandlung von Krebs und genetisch bedingten Erkrankungen erhalten.

Patienten knnen ihre DNA und ihre Krebstumor-DNA schneller und gnstiger denn je sequenzieren lassen, was bedeutet, dass sich die Krankheit einer einzelnen Person wesentlich besser nachvollziehen lsst als noch vor einigen Jahren. Dr. Mike Lynch sagte: "Die Herausforderung liegt jetzt in der Analyse, der Interpretation und dem Schutz der riesigen Mengen von Sequenzdaten, die durch diese neue Technologie generiert werden. Kurz gesagt ist ein entscheidender Teil davon ein Problem der Big-Data-Analyse, und ich denke, dass die ausgefeilten Algorithmen von Sophia und Genalys die klinische Genauigkeit liefern knnen, die fr eine sinnvolle und gezielte Behandlung erforderlich ist."

Bis vor kurzem hatten nur Forscher Zugriff auf die Art von Informationen, die Sophia Genetics nun in die Hnde von Klinikern legt, indem sie ihnen fr Europa zertifizierte Qualittssicherung in Sachen Genauigkeit, Zuverlssigkeit, Reproduzierbarkeit und Datensicherheit bietet. Durch das zum Patent angemeldete Verfahren zum Schutz von Genomdaten von Sophia Genetics, kombiniert mit der Fachkompetenz bei der Sicherung von Patientendaten von Invoke, ist Sophia Genetics seinen Konkurrenten um einige Schritte voraus und hlt dabei die strikten europischen Datenschutzgesetze vollstndig ein.

Hinter Sophia Genetics steht ein Trio von Mitbegrndern, die anerkannte Fachleute auf den Gebieten der Genetik, Bioinformatik und Molekularbiologie sind und ein hochqualifiziertes Team aus Doktortiteltrgern von den 10 weltweit fhrenden Universitten zusammengestellt haben. In nur drei Jahren hat Sophia Genetics Bioinformatik-Pipelines und Visualisierungstools fr ber 70 kommerzielle Panels und geschtzte magefertigte Panels entwickelt und weitet diese Kapazitt auf ganze Exome und Genome aus. Das Unternehmen erhlt fr jede untersttzte Pipeline eine CE-IVD-Kennzeichnung und wurde nach ISO 13485 zertifiziert.

"Die Medizin verndert sich, und ich bin stolz auf alles, was Sophia Genetics fr eine verbesserte Diagnose und Behandlung von Krankheiten tut. Die neue Finanzierung wird es uns gestatten, schneller auf die europischen Mrkte vorzudringen. Insbesondere Invoke Capital bringt umfangreiches Fachwissen im Bereich Datensicherheit mit, das unser Datenbankangebot fr genetische Sequenzierung sofort strken wird", sagte Jurgi Camblong, CEO von Sophia Genetics.

Hinweise an die Herausgeber

Informationen zu Sophia Genetics

Read more:
Sophia Genetics beschafft Kapital durch Serie-B-Runde unter Fhrung von Invoke Capital

Recommendation and review posted by Bethany Smith

LONDRES et LAUSANNE, Suisse, July 8, 2014 /PRNewswire/ --

L'investissement a pour but d'acclrer l'adoption europenne des analyses cliniques des pathologies gntiques

Sophia Genetics, leader europen dans le domaine de la mdecine base sur les donnes, a obtenu 13,75millions$ au cours d'un tour de financement de srie B organis par Invoke Capital - une socit fonde par le Dr Mike Lynch - Swisscom et Endeavour Vision.

Sophia Genetics est un pionnier en matire de mdecine base sur les donnes, un domaine de convergence ncessitant une expertise approfondie en matire de squenage de prochaine gnration (NGS) associe des algorithmes trs prcis, extensibles et prdictifs pour le diagnostic des pathologies gntiques. Grce cet investissement, Sophia peut accder Genalys, une socit appartenant Invoke dont les mathmaticiens bass Cambridge traitent les informations gnomiques avec des mthodes big data. Cette combinaison signifie que les cliniciens et les hpitaux dans l'ensemble de l'Europe peuvent obtenir des analyses cliniques trs prcises pour le diagnostic prcoce et le traitement optimis du cancer et des pathologies gntiques.

L'ADN des patients et celui de leurs tumeurs cancreuses peuvent tre squencs avec une rapidit et selon des cots ingals, ce qui signifie que la pathologie d'une personne peut tre comprise de faon inimaginable il y a seulement quelques annes. Selon le Dr M. Lynch: Le dfi se situe dsormais dans l'analyse, l'interprtation et la protection des normes quantits de donnes de squence gnres par cette nouvelle technologie. En bref, un lment cl est le problme de l'analyse des big data et je pense que les algorithmes sophistiqus de Sophia et de Genalys peuvent fournir la prcision clinique ncessaire pour des traitements cibls pertinents.

Il n'y a pas si longtemps, seuls les chercheurs avaient accs aux informations que Sophia Genetics propose dsormais aux cliniciens avec une assurance qualit homologue en Europe, pour la prcision, la fiabilit, la reproductibilit et la confidentialit. L'approche, en attente d'un brevet, de confidentialit gnomique de Sophia Genetics associe la propre expertise d'Invoke pour la protection des donnes du patient, signifie que Sophia Genetics est en avance sur le reste du secteur et totalement conforme aux lois rigoureuses de protection des donnes en Europe.

Les trois fondateurs de Sophia Genetics sont des experts reconnus dans le domaine de la gntique, de la bio-informatique et la biologie molculaire. Ils ont mis en place une quipe particulirement qualifie, compose de titulaires de doctorats des 10meilleures universits au monde. En l'espace de trois ans seulement, Sophia Genetics a dvelopp des pipelines bio-informatiques et des outils de visualisation pour plus de 70panels commerciaux et panels propritaires et est en train d'tendre cette capacit aux exomes et gnomes. La socit a obtenu la marque CE-IVD pour chaque pipeline pris en charge et a reu une certification ISO 13485.

La mdecine volue et je suis fier de tous les travaux entrepris par Sophia Genetics pour l'amlioration des diagnostics et des traitements des maladies. Ce nouveau financement nous permettra de pntrer plus rapidement dans les marchs europens. Invoke Capital fournit notamment un degr d'expertise pour la scurit des donnes dans le nuage et en matire d'extensibilit qui vont renforcer immdiatement notre offre de base de donnes de squenage gntique, dclare Jurgi Camblong, PDG de Sophia Genetics.

Remarques l'intention des diteurs

propos de Sophia Genetics

Read this article:
Sophia Genetics conclut un tour de financement de srie B organis par Invoke Capital

Recommendation and review posted by Bethany Smith

Gilbert, Arizona (PRWEB) July 08, 2014

The top Gilbert pain management clinic, Arizona Pain Specialists, is now offering over 25 effective back pain treatment options. The Arizona pain management center has now added regenerative medicine options along with cutting edge back pain treatments, which often provide over a year of pain relief. Call (480) 535-6722 to take advantage of the options.

Back pain affects 90% of individuals at some point. It may be disabling and prevent those affected from working, playing with one's kids or enjoying life. Arizona Pain continues to add back pain treatment options at its Gilbert location, combining both traditional and alternative therapies for optimal relief.

Board Certified pain management doctors work closely with chiropractors, acupuncturists and physical rehabilitation providers to customize treatment regimens for patients. New additions to the options include regenerative medicine treatments with stem cell procedures. These include both amniotic and bone marrow derived procedures.

Cutting edge additions to the interventional procedures include spinal cord stimulator implants and radiofrequency ablation procedures. These are excellent options for those suffering from chronic low back pain to provide much needed relief.

The Gilbert chiropractors at Arizona Pain offer revolutionary spinal decompression therapy, which is FDA cleared and effective in over 85% of patients. With all of the options available now with pain management Gilbert AZ trusts, Arizona Pain achieves over 95% success rates.

Over 50 insurance plans are accepted at the Center including PPO's, some HMO's, Medicare, Medicaid, personal injury liens, workers compensation and self pay as well. Call (480) 535-6722 for more information and scheduling.

See the article here:
Top Gilbert Pain Management Center, Arizona Pain Specialists, Now Offering Over 25 Nonoperative Back Pain Treatments

Recommendation and review posted by simmons

What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ?
Dr. Nandini Gokulchandran from Neurogen Brain and Spine Institute explains what goes wrong in the brain of a child with Autism Spectrum Disorder? Stem Cell Therapy done at Dr Alok Sharma...

By: Neurogen Brain and Spine Institute

Read this article:
What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ? - Video

Recommendation and review posted by simmons

Scotiabank Charity Challenge 2014
Three years ago, Spinal Cord Injury BC asked the organizers of the Scotiabank Charity Challenge for one simple thing. The result was even better than anyone could have imagined. Take a look...

By: Spinal Cord Injury BC

See the rest here:
Scotiabank Charity Challenge 2014 - Video

Recommendation and review posted by sam

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Steve Graff stephen.graff@uphs.upenn.edu 215-349-5653 University of Pennsylvania School of Medicine

PHILADELPHIA A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this important classification.

In early-stage clinical trials at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

"Our early findings reveal tremendous promise for a desperate group of patients, many of whom have been able to return to their normal lives at school and work after receiving this new, personalized immunotherapy," said the Penn research team's leader, Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of Translational Research in the Abramson Cancer Center of the University of Pennsylvania. "Receiving the FDA's Breakthrough Designation is an essential step in our work with Novartis to expand this therapy to patients across the world who desperately need new options to help them fight this disease."

The FDA's Breakthrough Therapy designation, created in 2012, is intended to expedite the development and review of new medicines both drugs and biologic agents that treat serious or life-threatening conditions, if the therapy has demonstrated substantial improvement over available therapies. The FDA has previously granted Breakthrough Therapy to only four other biologic agents.

In August 2012, Penn announced an exclusive global research and licensing agreement with Novartis to further study, develop and commercialize personalized chimeric antigen receptor (CAR) T cell therapies for the treatment of cancers. Trials employing CTL019 began in the summer of 2010 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL), and are now underway for adult and pediatric patients with ALL, and patients with non-Hodgkin lymphoma and myeloma. Penn and Novartis are also investigating the next generation of CAR therapies, with trials for mesothelioma, ovarian, breast and pancreatic cancer now in early stages.

During the 2013 annual meeting of the American Society of Hematology, the Penn research team announced study results of the first 27 ALL patients(22 children and five adults) treated with CTL019: 89 percent of the patients had a complete response to the therapy. The first pediatric ALL patient to receive the Penn therapy celebrated the second anniversary of her cancer remission in May, and the first adult patient remains in remission one year after receiving the therapy.

The investigational treatment pioneered by the Penn team begins by removing patients' T cells via an apheresis process similar to blood donation, then genetically reprogramming them in Penn's Clinical Cell and Vaccine Production Facility. After being infused back into patients' bodies, these newly built "hunter" cells both multiply and attack, targeting tumor cells that express a protein called CD19. Tests reveal that the army of hunter cells can grow to more than 10,000 new cells for each single engineered cell patients receive.

Go here to read the rest:
Penn's immunotherapy for leukemia receives FDA's Breakthrough Therapy designation

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

6-Jul-2014

Contact: Jia Liu liujia@genomics.cn BGI Shenzhen

July 7, 2014, Shenzhen, China Researchers from BGI, working within the Metagenomics of the Human Intestinal Tract (MetaHIT) project, and in collaboration with other institutions around the world , have established the highest quality integrated gene set for the human gut microbiome to date- a close-to-complete catalogue of the microbes that reside inside us and massively outnumber our own cells. While the roughly 20,000 genes in the human genome have been available for over a decade, the gene catalog of the microbiome, our much larger "other genome", has to date been much more poorly understood and characterized.

The data released from this study should facilitate further research on the interactions between human and microbial genomes, and brings us closer to an understanding of how to maintain the microbial balance that keeps us healthy. The latest study was published online today in the journal Nature Biotechnology.

Each of our guts is colonized by more than 3 pounds of microorganisms that can break down toxins, manufacture vitamins and essential amino acids, and form a barrier against invaders. However, until now there has been a lack of comprehensive and uniformly processed database resources cataloging the human gut microbiota around the world, which has hindered our knowledge of the genetic and functional mechanism of human gut microbes.

In this study, researchers established a catalog of the human gut microbial genes by processing 249 newly sequenced samples and 1,018 published samples from MetaHIT, Human Microbiome Project (HMP) and a large diabetes study from China, as well as 511 sequenced genomes of gut-related bacteria and archaea. This expanded research is at least three times larger than the cohorts used for previous gene catalogs.

Based upon the catalog, researchers investigated the gut microbiota of healthy Chinese and Danish adults, and found the two cohorts greatly differed in nutrient metabolism as well as xenobiotic detoxification, which might be influenced by the differences in diet and environment. In addition, they observed enrichment in possible antibiotic resistance genes both at the population level (penicillin resistance in Danes and multidrug resistance in Chinese) and in the individual-specific genes, which highlighted the need for close monitoring of direct and indirect exposure to antibiotics.

Individual-specific genes contributed overwhelmingly to the increased total gene number in the integrated gene catalog and were overrepresented in genes responsible for the synthesis of cell wall components, DNA-related functions such as transposases, endonucleases and DNA methylases and encoding phage-related proteins. Such individual-specific genes likely reflect adaptation and might reflect the distinct combination of genetic, nutritional and medical factors in a host.

This nonredundant reference catalog of over 9.8 million genes is freely accessible through the website and the data have also been deposited in BGI's GigaScience Database, GigaDB and the SRA. It provides a much expanded and invaluable resource for global researchers to more deeply explore the geographical, genetic, temporal and physiological characteristics of gut microbes.

See the article here:
BGI presents a high-quality gene catalog of human gut microbiome

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise WASHINGTON, DC The American Society of Nephrology (ASN) and the ASN Foundation for Kidney Research will fund $2.8 million in original, meritorious research in 2014 to improve care for the more than 20 million Americans with kidney disease, and for kidney patients worldwide.

The ASN Foundation for Kidney Research helps prevent and cure kidney diseases through research and innovation. By adding 19 new research projects to a strong funding portfolio, the ASN Foundation for Kidney Research helps kidney professionals apply their talents to make a positive difference in the lives of millions, Chair of the Board of Directors Bruce A. Molitoris, MD, FASN, said.

The Ben J. Lipps Research Fellowship Program supports nephrology fellows who will advance the understanding of kidney biology and disease. The 2014 class includes:

Ben J. Lipps Research Fellows Akinwande A. Akinfolarin, MBBS, Brigham and Womens Hospital Pei-Lun Chu, MD, PhD, University of Virginia Daniel Fantus, MD, University of Pittsburgh Silvia Ferr, PhD, University of Texas Southwestern Michelle M. O'Shaughnessy, MD, MBChB, Stanford University Donald E. Wesson Research Fellow Nicholas Zwang, MD, Massachusetts General Hospital Joseph A. Carlucci Research Fellow Gene- Yuan Chang, MD, University of California San Francisco Sharon Anderson Research Fellow Moshe Shashar, MD, Boston Medical Center ASN Foundation for Kidney Research Fellows Javier A. Neyra, MD, University of Texas Southwestern Rabi Yacoub, MD, Ichan School of Medicine at Mount Sinai

The foundations Career Development Grants Program helps young investigators achieve independent research careers. Funding supports basic and clinical research in adult and pediatric nephrology, immunology and genetics directly relevant to human membranous nephropathy, glomerular diseases and idiopathic focal segmental glomerulosclerosis (FSGS). The 2014 recipients are:

Carl W. Gottschalk Research Scholar Grants Michael Butterworth, PhD, University of Pittsburgh Kirk N. Campbell, MD, Ichan School of Medicine at Mount Sinai Krzysztof Kiryluk, MD, Columbia University Timmy C. Lee, MD, FASN, University of Alabama at Birmingham Ethan Marin, MD, PhD, Yale School of Medicine Brian B. Ratliff, PhD, New York Medical College Matthias Wolf, MD, University of Texas Southwestern John Merrill Grant in Transplantation Martin H. Oberbarnscheidt, MD, PhD, University of Pittsburgh The NephCure Foundation-ASN Foundation for Kidney Research Grant Heon Yung Gee, MD, PhD, Boston Childrens Hospital

The 2014 grant recipients will propel advances in patient care and outcomes through basic, translational and clinical research, Dr. Molitoris said. ASN is delighted to support this research and foster the careers of the next generation of investigators who will advance care for kidney patients.

The ASN Foundation for Kidney Research was established in 2012 and funds the Career Development Grants Program, the Ben J. Lipps Research Fellowship Program, and the Student Scholar Grants Program. The Ben J. Lipps Research Fellowship Program is supported by educational donations provided by the American Renal Patient Care Foundation, Inc., Amgen, ASN, Baxter, and Fresenius Medical Care. For more information on the ASN Foundation for Kidney Research or its Grants Program, please visit http://www.asn-online.org/foundation or contact grants@asn-online.org, 202.618.6990.

View original post here:
ASN Foundation for Kidney Research Funds $2.8 Million in Research Grants

Recommendation and review posted by Bethany Smith

Researcher Summer Goodson is used to getting snickers when she tells people shes studying male infertility.

Its expected, said Goodson, a post-doctoral research associate at the UNC Nutrition Research Institute in Kannapolis. Its a sensitive subject. But its a fascinating subject.

Goodson is looking into the hypothesis that the nutrient betaine, commonly found in foods such as beets and spinach, could improve sperm function in certain men.

Our hope is to see improvement in sperm function, Goodson said. It may have potential for (treating) male infertility, which is a growing problem in the United States.

But before we get to the details, let me tell you how she got to this point. Like a lot of things in science, serendipity played a role.

About six years ago, graduate student Amy Johnson was studying brain development in mice at UNC Chapel Hill. She looked at the effect of a particular gene that helps metabolize the nutrient choline into betaine in the body. She deleted that gene in the mice, expecting to discover effects on brain development. Instead, she wound up with male mice that were infertile.

Trying to figure out what was going on, Johnson contacted an expert in reproductive biology at UNC. Through her, she met Goodson, who was working on her doctorate in cell and developmental biology. They worked together, speculating on the reasons for the infertile mice and what further testing should be done.

Eventually, Johnson studied human males with a particular variant in the same gene that was missing in her research mice. The men had similar problems with sperm function. Their sperm motility was not as robust as that for men who didnt have the variant, Goodson said.

Fast forward to 2013. Johnson had moved to another research lab at UNC, and Goodson, who had finished her doctorate, was invited to the Kannapolis campus to speak about her work. While there, she happened to have a conversation with Dr. Steven Zeisel, the nutrition institutes director and Johnsons former supervisor.

Zeisel recalled Johnsons research with the infertile mice. He said she had noticed the mice had low levels of betaine, and when she put that nutritional supplement in their drinking water, their sperm function had improved. Zeisel suggested that giving betaine to human males with the genetic variant might improve their sperm function.

See the rest here:
Kannapolis research institute: Could nutrition affect male infertility?

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, July 7, 2014Cycling is a popular activity that offers clear health benefits, but there is an ongoing controversy about whether men who ride have a higher risk of urogenital disorders such as erectile dysfunction, infertility, or prostate cancer. The results of a study of nearly 5,300 male cyclists who participated in the Cycling for Health UK Study are presented in an article in Journal of Men's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Men's Health website at http://online.liebertpub.com/doi/full/10.1089/jomh.2014.0012 until August 7, 2014.

Milo Hollingworth, MBBS and Alice Harper, MBBS, University College London Medical School, and Mark Hamer, PhD, University College London, analyzed the risk for these three disorders in relation to the amount of weekly cycling time, ranging from <3.75 hours up to >8.5 hours per week. They report their findings in the article "An Observational Study of Erectile Dysfunction, Infertility and Prostate Cancer in Regular Cyclists: Cycling for Health UK Study."

"Physicians should discuss the potential risks and health benefits of cycling with their patients, and how it may impact their overall health," says Ajay Nehra, MD, Editor-in-Chief of Journal of Men's Health and Chair, Department of Urology, Director, Men's Health, Rush University Medical Center, Chicago, IL.

###

About the Journal

Journal of Men's Health is the premier peer-reviewed journal published quarterly in print and online that covers all aspects of men's health across the lifespan. The Journal publishes cutting-edge advances in a wide range of diseases and conditions, including diagnostic procedures, therapeutic management strategies, and innovative clinical research in gender-based biology to ensure optimal patient care. The Journal addresses disparities in health and life expectancy between men and women; increased risk factors such as smoking, alcohol abuse, and obesity; higher prevalence of diseases such as heart disease and cancer; and health care in underserved and minority populations. Journal of Men's Health meets the critical imperative for improving the health of men around the globe and ensuring better patient outcomes. Tables of content and a sample issue can be viewed on the Journal of Men's Health website at http://www.liebertpub.com/jmh.

About the Societies

Excerpt from:
Does cycling increase risk for erectile dysfunction, infertility, or prostate cancer?

Recommendation and review posted by Bethany Smith

07.07.2014 - (idw) Deutsches Zentrum fr Neurodegenerative Erkrankungen e.V. (DZNE)

People whose genome carries certain variations have a particularly high risk of developing Parkinson's disease. In particular, genetic variants in a gene referred to as GBA1 (glucocerebrosidase) are associated to an increased risk for Parkinsons. Researchers of the German Center for Neurodegenerative Diseases (DZNE) and the Hertie Institute for Clinical Brain Research have now pinpointed the consequences that genetic variations in GBA1 have on neurons consequences that had been largely undetermined to date. Using stem cells, they found that mutations affecting GBA1 impair calcium metabolism and the cells garbage disposal that normally digests and recycles defective substances including alpha-synuclein, the protein that accumulates in the brain of patients suffering from Parkinsons. This research shows a link between alterations in the GBA1 gene and cellular dysfunctions in Parkinsons disease for the first time. It also suggests potential targets for drugs and biomarkers that could be useful for diagnosis. The study is published in the journal Nature Communications.

In people suffering from Parkinsons, brain cells that are supposed to produce a neurotransmitter called dopamine, die off over time, making it difficult for these patients to control their movements. They may also suffer from insomnia and depression. And as the illness progresses, they may also develop dementia. To date, there is no cure for Parkinsons disease and the actual triggers of the death of neurons, i.e. of the so-called neurodegeneration, are still unknown. However, mutations of a certain gene referred to as GBA1, have been identified as a major risk factor. This gene contains the blueprint of an enzyme, called glucocerebrosidase, that is involved in the processing of certain lipids, explains DZNE researcher Michela Deleidi, who also works at the Hertie Institute for Clinical Brain Research. Alterations in this gene do not necessarily lead to Parkinsons. In fact, whereas people with mutations in both copies of the gene are affected by a metabolic disorder called Gauchers disease, both Gauchers disease patients and individuals with a mutation in just one copy of the gene are predisposed to develop Parkinsons.

Up to now, the consequences these mutations have on nerve cells were largely unexplored. Studies addressing the effect of these mutations in Parkinsons disease have not been performed yet, observes Deleidi. She therefore set out to elucidate the consequences of the genetic mutations. The study involved a team based in Tbingen including Professor Thomas Gasser, as well researchers in Italy and the United States.

Induced stem cells

Human nerve cells are not readily accessible and it is very difficult to cultivate such cells in the laboratory if they are obtained, for instance, through a surgical procedure. Hence, Deleidi and her colleagues chose a different approach: they took skin cells from Parkinsons and Gauchers patients harbouring mutations of the GBA1 gene and converted them into induced pluripotent stem cells by manipulating their genetic programme. Stem cells are unspecialized cells that have the potential to evolve into virtually any type of cell in the body. We differentiated stem cells into dopamine-producing neurons, the scientist explains. These cells contained the patients DNA and therefore also the GBA1 gene mutations. Next, we investigated the effects that these mutations had on the cell. We looked at those effects which make the cell susceptible to neurodegeneration. Other neurons that also originated from patients, served as controls. However, in these cells the GBA1 mutations had been corrected by genetic engineering.

Various dysfunctions

Potential biomarkers

These results were consistent with other findings based on patient studies. Enzymes showing unusual behavior in the cell cultures also revealed reduced activity in the spinal fluid of patients. This comprised not only glucocerebrosidase. The activity of other enzymes involved in the metabolism of lipids was also reduced. Measurement of the enzyme activity may provide important clues to disease. These enzymes may serve as biomarkers, in other words as indicators that could be helpful for the diagnosis of Parkinson's disease, Deleidi points out.

The researchers also found increased concentrations of the protein alpha-synuclein in the nerve cells they studied in laboratory. This protein does play a key role in Parkinsons disease because it aggregates into microscopically small lumps, which are suspected to damage nerve cells.

Read more:
Parkinsons disease: genetic defect triggers multiple damages in neurons

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Gina DiGravio gina.digravio@bmc.org 617-638-8480 Boston University Medical Center

Boston - Researchers from the Biomedical Genetics division of the Boston University School of Medicine (BUSM) are part of a five-university collaboration receiving a $12.6 million, four-year grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to identify rare genetic variants that may either protect against, or contribute to Alzheimer's disease risk.

At BUSM, the Consortium for Alzheimer's Sequence Analysis (CASA) is led by Lindsay A. Farrer, PhD, Chief of Biomedical Genetics and professor of medicine, neurology, ophthalmology, epidemiology, and biostatistics, who is the principal investigator. Other Boston University investigators include Kathryn Lunetta, PhD, professor of biostatistics; Gyungah Jun, PhD, assistant professor of medicine, ophthalmology and biostatistics; and Richard Sherva, PhD, research assistant professor of medicine.

CASA investigators will analyze whole exome and whole genome sequence data generated during the first phase of the NIH Alzheimer's Disease Sequencing Program, an innovative collaboration that began in 2012 between NIA and the National Human Genome Research Institute (NHGRI), also part of NIH. They will analyze data from 6,000 volunteers with Alzheimer's disease and 5,000 older individuals who do not have the disease. In addition, they will study genomic data from 111 large families with multiple members who have Alzheimer's disease, mostly of Caucasian and Caribbean Hispanic descent to identify rare genetic variants.

"This is an exciting opportunity to apply new genomic technologies and computational methods to improve our understanding of the biological pathways underlying this disease," said Farrer. "The genes and pathways we identify as integral to the Alzheimer process may become novel therapeutic targets," he added.

Alzheimer's disease, a progressive neurodegenerative disorder, has become an epidemic that currently affects as many as five million people age 65 and older in the United States, with economic costs that are comparable to, if not greater than, caring for those of heart disease or cancer. Available drugs only marginally affect disease severity and progression. While there is no way to prevent this disease, the discovery of genetic risk factors for Alzheimer's is bringing researchers closer to learning how the genes work together and may help identify the most effective interventions.

This effort is critical to accomplishing the genetic research goals outlined in the National Plan to Address Alzheimer's Disease, first announced by the U.S. Department of Health and Human Services in May 2012 and updated annually. Developed under the National Alzheimer's Project Act, the plan provides a framework for a coordinated and concentrated effort in research, care, and services for Alzheimer's and related dementias. Its primary research goal is to prevent and effectively treat Alzheimer's disease by 2025.

With the current award, CASA joins the NHGRI Large-Scale Sequencing and Analysis Centers program, an NIH-supported consortium that provides large-scale sequence datasets and analysis to the biomedical community. CASA researchers will facilitate the analyses of all Alzheimer's Disease Sequencing Project (ADSP) and additional non-ADSP sequence data to detect protective and risk variants for Alzheimer's disease.

Original post:
Boston University researchers and collaborators receive $12.6 million NIH grant for AD

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine

PHILADELPHIA - Researchers from the Perelman School of Medicine at the University of Pennsylvania are part of a five-university collaboration receiving a $12.6 million, four-year grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to identify rare genetic variants that may either protect against, or contribute to Alzheimer's disease risk.

At Penn, the Consortium for Alzheimer's Sequence Analysis (CASA) is led by Gerard D. Schellenberg, PhD, professor of Pathology and Laboratory Medicine. Other Penn investigators are Li-San Wang, PhD, professor of Pathology and Laboratory Medicine; Adam Naj, PhD, senior scholar, Center for Clinical Epidemiology and Biostatistics, and Nancy Zhang, PhD, professor of Statistics, Wharton School.

CASA investigators will analyze whole exome and whole genome sequence data generated during the first phase of the NIH Alzheimer's Disease Sequencing Program, an innovative collaboration that began in 2012 between NIA and the National Human Genome Research Institute (NHGRI), also part of NIH. They will analyze data from 6,000 volunteers with Alzheimer's disease and 5,000 older individuals who did not have the disease. In addition, they will study genomic data from 111 large families with multiple Alzheimer's disease members, mostly of Caucasian and Caribbean Hispanic descent to identify rare genetic variants.

"By identifying additional Alzheimer's-related genes, the CASA team aims to find new therapeutic targets that will reduce the economic and human burden caused by this disease," said Schellenberg. "This is an exciting opportunity to apply new technologies to improve our understanding of the biological pathways underlying this devastating disease."

Alzheimer's disease, a progressive neurodegenerative disorder, has become an epidemic that currently affects as many as five million people age 65 and older in the United States, with economic costs that are comparable to, if not greater than, caring for those of heart disease or cancer. Available drugs only marginally affect disease severity and progression. While there is no way to prevent this disease, the discovery of genetic risk factors for Alzheimer's is bringing researchers closer to learning how the genes work together and may help identify the most effective interventions.

This effort is critical to accomplishing the genetic research goals outlined in the National Plan to Address Alzheimer's Disease, first announced by the U.S. Department of Health and Human Services in May 2012 and updated annually. Developed under the National Alzheimer's Project Act, the plan provides a framework for a coordinated and concentrated effort in research, care, and services for Alzheimer's and related dementias. Its primary research goal is to prevent and effectively treat Alzheimer's disease by 2025.

With the current award, CASA joins the NHGRI Large-Scale Sequencing and Analysis Centers program, an NIH-supported consortium that provides large-scale sequence datasets and analysis to the biomedical community. CASA researchers will facilitate the analyses of all Alzheimer's Disease Sequencing Project (ADSP) and additional non-ADSP sequence data to detect protective and risk variants for Alzheimer disease.

More here:
$12.6 million NIH grant to study genetics of Alzheimer's disease

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise PHILADELPHIA - Researchers from the Perelman School of Medicine at the University of Pennsylvania are part of a five-university collaboration receiving a $12.6 million, four-year grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to identify rare genetic variants that may either protect against, or contribute to Alzheimers disease risk.

At Penn, the Consortium for Alzheimers Sequence Analysis (CASA) is led by Gerard D. Schellenberg, PhD, professor of Pathology and Laboratory Medicine. Other Penn investigators are Li-San Wang, PhD, professor of Pathology and Laboratory Medicine; Adam Naj, PhD, senior scholar, Center for Clinical Epidemiology and Biostatistics, and Nancy Zhang, PhD, professor of Statistics, Wharton School.

CASA investigators will analyze whole exome and whole genome sequence data generated during the first phase of the NIH Alzheimers Disease Sequencing Program, an innovative collaboration that began in 2012 between NIA and the National Human Genome Research Institute (NHGRI), also part of NIH. They will analyze data from 6,000 volunteers with Alzheimers disease and 5,000 older individuals who did not have the disease. In addition, they will study genomic data from 111 large families with multiple Alzheimers disease members, mostly of Caucasian and Caribbean Hispanic descent to identify rare genetic variants.

By identifying additional Alzheimers-related genes, the CASA team aims to find new therapeutic targets that will reduce the economic and human burden caused by this disease, said Schellenberg. This is an exciting opportunity to apply new technologies to improve our understanding of the biological pathways underlying this devastating disease.

Alzheimers disease, a progressive neurodegenerative disorder, has become an epidemic that currently affects as many as five million people age 65 and older in the United States, with economic costs that are comparable to, if not greater than, caring for those of heart disease or cancer. Available drugs only marginally affect disease severity and progression. While there is no way to prevent this disease, the discovery of genetic risk factors for Alzheimers is bringing researchers closer to learning how the genes work together and may help identify the most effective interventions.

This effort is critical to accomplishing the genetic research goals outlined in the National Plan to Address Alzheimers Disease, first announced by the U.S. Department of Health and Human Services in May 2012 and updated annually. Developed under the National Alzheimers Project Act, the plan provides a framework for a coordinated and concentrated effort in research, care, and services for Alzheimers and related dementias. Its primary research goal is to prevent and effectively treat Alzheimers disease by 2025.

With the current award, CASA joins the NHGRI Large-Scale Sequencing and Analysis Centers program, an NIH-supported consortium that provides large-scale sequence datasets and analysis to the biomedical community. CASA researchers will facilitate the analyses of all Alzheimers Disease Sequencing Project (ADSP) and additional non-ADSP sequence data to detect protective and risk variants for Alzheimer disease.

We are delighted to support the important research being accomplished under this broad-based, collaborative effort. A team effort is vital to advancing a deeper understanding of the genetic variants involved in this complex and devastating disease and to the shared goal of finding targets for effective interventions, said NIH Director Francis Collins, MD, PhD.

See the original post:
Penn Medicine Researchers and Collaborators Receive $12.6 Million NIH Grant to Study Genetics of Alzheimer's Disease

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise Researchers from Case Western Reserve University School of Medicine are part of a five-university collaboration receiving a $12.6 million, four-year grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to identify rare genetic variants that may either protect against, or contribute to Alzheimers disease risk.

At Case Western Reserve School of Medicine, the Consortium for Alzheimers Sequence Analysis (CASA) is led by Jonathan Haines, PhD, chair of the department of epidemiology & biostatistics and director of the Institute for Computational Biology. Fellow Case Western Reserve investigator is William Bush, PhD, assistant professor of epidemiology and biostatistics.

CASA investigators will analyze whole exome and whole genome sequence data generated during the first phase of the NIH Alzheimers Disease Sequencing Program, an innovative collaboration that began in 2012 between NIA and the National Human Genome Research Institute (NHGRI), also part of NIH. They will analyze data from 6,000 volunteers with Alzheimers disease and 5,000 older individuals who do not have the disease. In addition, they will study genomic data from 111 large families with multiple members who have Alzheimers disease, mostly of Caucasian and Caribbean Hispanic descent to identify rare genetic variants.

Illuminating the hidden genetic architecture of Alzheimers disease will help identify therapeutic targets, and reduce the economic and personal burdens this devastating disease inflicts, Haines said. Combining the latest in DNA sequencing technologies and computational methods represents an exciting approach toward solving the riddle of this disease.

Alzheimers disease, a progressive neurodegenerative disorder, has become an epidemic that currently affects as many as five million people age 65 and older in the United States, with economic costs that are comparable to, if not greater than, caring for those of heart disease or cancer. Available drugs only marginally affect disease severity and progression. While there is no way to prevent this disease, the discovery of genetic risk factors for Alzheimers is bringing researchers closer to learning how the genes work together and may help identify the most effective interventions.

This effort is critical to accomplishing the genetic research goals outlined in the National Plan to Address Alzheimers Disease, first announced by the U.S. Department of Health and Human Services in May 2012 and updated annually. Developed under the National Alzheimers Project Act, the plan provides a framework for a coordinated and concentrated effort in research, care, and services for Alzheimers and related dementias. Its primary research goal is to prevent and effectively treat Alzheimers disease by 2025.

With the current award, CASA joins the NHGRI Large-Scale Sequencing and Analysis Centers program, an NIH-supported consortium that provides large-scale sequence datasets and analysis to the biomedical community. CASA researchers will facilitate the analyses of all Alzheimers Disease Sequencing Project (ADSP) and additional non-ADSP sequence data to detect protective and risk variants for Alzheimers disease.

We are delighted to support the important research being accomplished under this broad-based, collaborative effort. A team effort is vital to advancing a deeper understanding of the genetic variants involved in this complex and devastating disease and to the shared goal of finding targets for effective interventions, said NIH Director Francis Collins, MD, PhD.

Visit link:
Case Western Reserve University Researchers and Collaborators Receive $12.6 Million NIH Grant to Study Genetics of ...

Recommendation and review posted by Bethany Smith

July 7, 2014

Image Caption: The newly developed antibody brings hope for dogs. Credit: Michael Bernkopf / Vetmeduni Vienna

University of Veterinary Medicine Vienna

Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time, antibodies to treat cancer in dogs. The scientists published their research data in the journal Molecular Cancer Therapeutics.

As in humans, cancers in dogs have complex causes. The interaction of the environment, food, and genetic disposition are the most well known factors. Today nearly all methods of human medicine are basically available for dogs with cancer, but this was not true of cancer immunotherapy so far.

So-called cancer immunotherapy which is the treatment of tumors by the use of antibodies has been established and used very successfully in human medicine for about 20 years. Since cancer cells bear very specific antigens on the surface, the corresponding antibodies bind to these molecules and thus inhibit tumor growth. The mechanism that becomes effective is a destructive signal sent by the antibody to the inside of the cancer cell and initiates its death. In a second mechanism, the immune system of the patient also destroys the marked tumor in a more efficient way.

The target is nearly identical in humans and dogs

Josef Singer and Judith Fazekas, both lead authors of the study, discovered that a receptor frequently found on human tumor cells (epidermal growth factor receptor or EGFR) is nearly 100 percent identical with the EGF receptor in dogs. In human medicine EGFR is frequently used as the target of cancer immunotherapy because many cancer cells bear this receptor on their surface. The so-called anti-EGFR antibody binds to cancer cells and thus triggers the destruction of the cells. Due to the high similarity of the receptor in humans and dogs, this type of therapy should work well in dogs too, the scientists say. The binding site of the antibody to EGFR in man and dogs differs only in respect of four amino acids.

Antibody trimmed to dog

To ensure best possible binding of the antibody to cancer cells in dogs, the human antibody had to be trimmed to dog in the laboratory. In human medicine this process is known as the humanization of an antibody. The antibody originally produced in the mouse has to be adjusted to the species for which it is used. Singer and Fazekas replaced the corresponding elements in the humanized antibody with elements from the dog. In experiments on dog cancer cells in the laboratory it was found that the newly developed antibodies did, in fact, bind to canine cancer cells with greater specificity.

Follow this link:
Scientists Develop First Cancer Immunotherapy For Dogs

Recommendation and review posted by Bethany Smith

2014 Corn Belt Crop Tour - AgReliant Genetics Interview
2014 Corn Belt Crop Tour -- Interview with Tom Koch, Vice President of Research with AgReliant Genetics. Farms.com Risk Management Chief Commodity Strategist, Maurizio Agostino talks with Tom...

By: FarmMarkets

Go here to see the original:
2014 Corn Belt Crop Tour - AgReliant Genetics Interview - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research

Because the adult mammalian central nervous system has only limited intrinsic capacity to regenerate connections after injury, due to factors both intrinsic and extrinsic to the mature neuron, therapies are required to support the survival of injured neurons and to promote the long-distance regrowth of axons back to their original target structures. The retina and optic nerve are part of the CNS and this system is much used in experiments designed to test new ways of promoting regeneration after injury. Testing of therapies designed to improve RGCs viability also has direct clinical relevance because there is loss of these centrally projecting neurons in many ophthalmic diseases. Many different approaches are being trialed, targeting different receptor systems and/or different signaling pathways, some aimed at enhancing intrinsic growth capacity in injured RGCs, others aimed at reducing the impact of factors external to the neuron that suppress/restrict the regenerative response. An approach increasingly of interest involves the use of modified, replication-deficient viral vectors to introduce appropriate genes into injured cells in the visual pathway (gene therapy).

In the perspective article written by Prof Alan Harvey, from School of Anatomy, Physiology and Human Biology, The University of Western Australia, he summarized recent gene therapy research from his laboratory, using the rodent visual system as an experimental model, which is aimed at improving both the viability and regenerative capacity of injured adult RGCs. These perspectives were published in the Neural Regeneration Research (Vol. 9, No. 3, 2014).

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read more:
Gene therapy and the regeneration of retinal ganglion cell axons

Recommendation and review posted by Bethany Smith

2014 P1 English Course Final presentation "Personalized Medicine"
2014 1 This video shows a final presentation of a freshman. He is talking about "Personalized...

By: ProjectBasedEnglish

Go here to see the original:
2014 P1 English Course Final presentation "Personalized Medicine" - Video

Recommendation and review posted by sam

Top 16 Safe Alzheimer Stem Cell Therapy Options Worldwide
The cure for Alzheimer #39;s has not yet been found, yet, the miraculous stem cells have been effective in treating the symptoms of the disease and re-establishing neural connections. Available...

By: placidways

Visit link:
Top 16 Safe Alzheimer Stem Cell Therapy Options Worldwide - Video

Recommendation and review posted by simmons

Stem Cell Therapy and Platelet Rich Plasma (PRP) Therapy

By: DR Kyle Kinmon

Read the original:
Stem Cell Therapy and Platelet Rich Plasma (PRP) Therapy - Video

Recommendation and review posted by simmons

Council of Scientific and Industrial Research (CSIR) Centre for Cellular and Molecular Biology (CCMB) Director, Dr Ch. Mohan Rao today claimed that the heart disease can be treated without surgeries in future.

Addressing after inaugurating the 19th Annual conference of the Cardiological Society of India (CSI-AP Chapter) here, Dr Rao said that in the recent research in molecular biology found that 'heart' too have 'stem cells' which will help to automatically build the damaged part of any organ.

He said that further research also going with collaboration of other foreign institutions on how to bring the 'stem cells' out and repair.

Once the solution is found, the cardiac diseases can be healed with surgery, Dr Rao said.

''This development will make the stem cell based therapy replace the chemical based therapy in Cardiology,'' he added.

Irregular eating habits and busy lifestyle are among the major causes of the cordial illness, he said and advised to the youth to follow healthy lifestyle to avoid heart related problems.

While talking about the latest research, he said, ''To reduce the deaths due to cardiac illness the CCMB is working along with the scientists from Japan, the US and Italy to develop the an easier way to treatment.''

Dr Rao also given a clarion call to Cardiology experts to come forward for joint research on cardiac problems.

Encouraging the research in Cardiology, Dr Rao also invited the young medicos to visit the CCMB campus and work with the institute.

Discussing various kinds of heart diseases, he said, ''Dilated Cardiomyopathy is one of the most common heart disease among the children.''

Read more:
Cardiac diseases to be treated without surgeries soon as stem cells found

Recommendation and review posted by Bethany Smith

Federal funding blocked mainly over opposition to use of blastocysts

PORTSMOUTH Dr. Amy Sievers, an oncologist at Portsmouth Regional Hospital, does stem cell transplants with great success for her patients and is a firm advocate for stem cell research.

Sievers is allowed to do stem cell blood transplants because she does not use the source of controversy, embryonic stem cells. Instead, she can use stem cells from bone marrow, where blood is made. The cells can become new blood for transfusion into patients with blood-related cancers like leukemia.

"When we get past the chemo and radiation, the hope is we can replace blood and give the patient healthy blood and a chance to build a good immune system," Sievers said.

Parents saving cord blood when they give birth is an option, but Dr. Alexandra Bonesho of Core Physicians in Epping said it is very costly for the patient, is not covered by insurance and is not something pediatricians recommend widely unless there is a reason.

"It's not something we use as a practical course of events," Bonesho said. "Cord blood banking is very expensive, less so if the blood stem cells are donated to the National Cord Blood Bank. In most cases, the chance that you will need it for your own child is unlikely, unless there is already a known condition in the family."

For example, if there is a history of leukemia in another child, it may be worthwhile. Bonesho said in a case like that, having the baby's own blood stem cells can be the perfect answer.

"However, chances are good that if there is a sibling, they may also be a good match if a bone marrow transplant is needed," Bonesho said. "However, transplants are not the normal course of treatment in children with leukemia."

That being said, the cord blood could eventually be used for research in the future to find a cure for diseases like sickle cell anemia, Bonesho said.

Federal funding for much stem cell research is blocked mainly over the opposition to using embryonic stem cells. The cells come from blastocysts (fertilized eggs) from an in-vitro facility. The blastocysts are excess and are usually donated by people who have already been successfully treated for fertility problems.

Originally posted here:
The promise and hazards of stem cell research

Recommendation and review posted by Bethany Smith

The Night Shift Anatomy of a Night Shift Scene (Behind-The-Scenes) Get an insider's look at the production of a remarkable scene from The Night Shift episode Storm Watch. Subscribe for more The Night Shift!: http://bit.l

By: The Night Shift

Read this article: The Night Shift Anatomy of a Night Shift Scene (Behind-The-Scenes) Video

Infomercial Production Best Infomercial for Nanotechnology Infomercial Production. This is still one of the best nanotechology applications which hit TV through this infomercial production. Infomercial production companies are still great at showcasing

By: Quantum Ad Ventures Inc.

Read the original here: Infomercial Production Best Infomercial for Nanotechnology Video

Spitali Medicine TV ad 33 sec Client: Spitali Medicine Concept and Production: Ikon Studio.

By: Ikon Studio

Originally posted here: Spitali Medicine TV ad 33 sec Video

NEW YORK, June 18 2014 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue: Biotechnology in Food Production Market Forecast 2014-2024 http://www.reportlinker.com/p02148717/Biotechnology-in-Food-Production-Market-Forecast-2014-2024.html

More here:
production IPS Cell Therapy IPS Cell Therapy

Recommendation and review posted by Bethany Smith